Kyushu Irbesartan intervention trial for improvement of hypertension, glucose and lipid metabolism in hypertensive patients

Kyushu Irbesartan intervention trial for improvement of hypertension, glucose and lipid metabolism in hypertensive patients - Effects on metabolism by irbesartan trial in essential hypertensive patients (MEISTRE)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008188

Enrollment

100

Registered

2012-07-01

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

Prescribe irbetan (100mg) to essential hypertensive patients. If the blood pressure does not become within normal limits, another 100mg of irbetan or other hypertension medicine involved in RA pathway

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The hypertensive patient who meet the following criteria. 1) untreated patient 2) The patients who have 140/90 mmHg or more. In the case of diabetes, 130/80 or more. 3) The patients whose agreement to exam participation is obtained in the document

Exclusion criteria

Exclusion criteria: The patients who meet the following criteria will be excluded. A. The patient who has been prescribed the medicine involved in RA pathway for 8 weeks or more. b.HbA1c 10.0% or more. C. LDL-cholesterole 180 mg/dL or more. D. BMI35 or more E. The patient who corresponds to the taboo or prudent usage of irubetan.

Design outcomes

Primary

Measure	Time frame
Improvement of glucose and lipid profiles by the treatment of irbesartan	—

Secondary

Measure	Time frame
To evaluate the Improvement of pancreas b cell function by the treatment of irbesartan, the ratio of insulin and proinsulin will be analyzed.	—

Countries

Japan

Contacts

Public ContactMasatoshi Nomura

Kyushu University Hospital Division of Endocrinology and Metabolism

nomura@med.kyushu-u.ac.jp092-642-5293

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026